A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid Hemangioendothelioma

Protocol: 
AAAR4308
Phase: 
II

A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid Hemangioendothelioma

The purpose of this study is to determine the safety and effectiveness of
the study drug in patients with Metastatic Epithelioid Hemangioendothelioma
(EHE). The study drug is called trametinib. Trametinib could shrink your
cancer but it could also cause side effects. Researchers hope to learn if
the study drug will shrink the cancer by at least 30% compared to its
present size. Trametinib has already been FDA-approved to treat other
cancer. There will be up to 27 people taking part in this study.

Are you Eligible? (Inclusion Criteria)

1. Patients must have confirmed unresectable or metastatic Epithelioid
Hemangioendothelioma (EHE).
2.Patients must have measurable disease defined as ≥ 2 cm with conventional
techniques or ≥ 1cm on spiral CT scan.
3. Patients previously treated with drug therapy for EHE are eligible.
4. Patients must be 18 years or older.
5. Patients must have ECOG performance status of ≤ 2 or Karnofsky ≥ 60%

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States